Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study. Issue 8 (27th August 2019)

• Record Type: Journal Article
• Authors: Stack, Austin G; Johnson, Michelle Elizabeth; Blak, Betina; Klein, Alyssa; Carpenter, Lewis; Morlock, Robert; Maguire, Andrew R; Parsons, Victoria L
• Is Part Of: BMJ open. Volume 9:Issue 8(2019)
• Publication Date: 2019-08-27
• Subjects: chronic renal failure -- dialysis -- end-stage renal failure -- epidemiology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-031550
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: Evaluate the association between gout and risk of advanced chronic kidney disease (CKD). Design: Retrospective matched cohort study. Setting: UK Clinical Practice Research Datalink. Participants: The analysis included data for 68 897 patients with gout and 554 964 matched patients without gout. Patients were aged ≥18 years, registered at UK practices, had ≥12 months of clinical data and had data linked with Hospital Episode Statistics. Patients were excluded for history of advanced CKD, juvenile gout, cancer, HIV, tumour lysis syndrome, Lesch-Nyhan syndrome or familial Mediterranean fever. Primary and secondary outcome measures: Advanced CKD was defined as first occurrence of: (1) dialysis, kidney transplant, diagnosis of end-stage kidney disease (ESKD) or stage 5 CKD (diagnostic codes in Read system or International Classification of Diseases, Tenth Revision); (2) estimated glomerular filtration rate (eGFR) <10 mL/min/1.73 m²; (3) doubling of serum creatinine from baseline and (4) death associated with CKD. Results: Advanced CKD incidence was higher for patients with gout (8.54 per 1000 patient-years; 95% CI 8.26 to 8.83) versus without gout (4.08; 95% CI 4.00 to 4.16). Gout was associated with higher advanced CKD risk in both unadjusted analysis (HR, 2.00; 95% CI 1.92 to 2.07) and after adjustment (HR, 1.29; 95% CI 1.23 to 1.35). Association was strongest for ESKD (HR, 2.13; 95% CI 1.73 to 2.61) and was present for eGFR <10 mL/min/1.73 m² (HR, 1.45; 95% CI 1.30 to 1.61) and serum creatinine doubling (HR, 1.13; 95% CI 1.08 to 1.19) but not CKD-associated death (HR, 1.14; 95% CI 0.99 to 1.31). Association of gout with advanced CKD was replicated in propensity-score matched analysis (HR, 1.23; 95% CI 1.17 to 1.29) and analysis limited to patients with incident gout (HR, 1.28; 95% CI 1.22 to 1.35). Conclusions: Gout is associated with elevated risk of CKD progression. Future studies should investigate whether controlling gout is protective and reduces CKD risk.